BrainXell focuses on neural cells for therapeutic development. It was founded in 2015 with a startup grant to Professor Su-Chun Zhang by the Discovery to Product (D2P) program of the University of Wisconsin Madison. It is based on the proprietary technology in directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neural progenitors, expansion of committed neural progenitors to large quantities, and rapid maturation to functional neurons and glia. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells for as well as provide services to pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXell’s goal is to make our brain healthy and well.

+1 608 316 4733  |  info@brainxell.com


Neuron Type Neuronal Purity Time to Use Catalog Number
Currently Available
Spinal Cord Motor Neurons >90% 5 - 10 days BX-0100
Dopaminergic Neurons
>80% 10 - 18 days BX-0200
Glutamatergic Neurons >90% 7 - 14 days BX-0300
GABAergic Neurons >90% 7 - 14 days BX-0400
Mixed Cortical Neurons >90% 7 - 14 days BX-0500
Newly Introduced
Medium Spiny Striatal GABAergic Neurons >70% 7 - 14 days BX-0700
Parvalbumin-Enriched Cortical GABAergic Neurons >10% 7 - 14 days BX-0450
Layer V Cortical Glutamatergic Neurons >80% 7 - 14 days BX-0350

  • Neuronal purity represents the percentage of a specific neuron type out of all neurons. For all types, overall purity of neurons out of all cells is >80%.
  • Mixed Cortical Neurons are 80% Glutamatergic and 20% GABAergic.
  • All neuron types are available with a ubiquitous GFP reporter upon request.
  • Please inquire about the availability of neuron types under development for evaluation.


Neurons from Specific iPSCs

Any of the neuron types listed under Products can be produced from customer-supplied induced pluripotent cells (iPSCs) or embryonic stem cells (ESCs). The iPSCs can be derived from either healthy controls, individuals with a sporadic disease, or individuals with a disease mutation. From the receipt of cells, delivery time is typically two to three months with quantities of up to half a billion neurons.

Large-Scale Production

Large batch sizes of up to two billion neurons are available for all neuron types.

In-House Assays for Motor Neuron Diseases

A range of custom assays can be performed on in-house models of two motor neuron diseases, spinal muscular atrophy and amyotrophic lateral sclerosis. Please inquire for assay and model specifics.


Discovery & Neurotoxicity

Motor neurons with a luciferase reporter show a typical S-curve pharmacological response.

High-Content Imaging
Neurons carrying a GFP-reporter can be used for high-content imaging with automated analysis of neuron morphology such as neurite number, length, and branching complexity.

Functional Activity – Calcium Influx
Calcium influx of mature neurons (Day 10) can be measured following electric field stimulation.

Functional Activity – Action Potentials
Action potential magnitude and frequency can be measured using traditional electrophysiology techniques.

Functional Activity – Multi-Electrode Array (MEA)
Spike activity over the entire culture can be monitored using multi-electrode array.

Regenerative Medicine

Neurological traumas, such as spinal cord injury, and neurodegenerative disorders, such as Parkinson’s disease, often lack effective treatment. Stem cell therapy presents a promising alternative. BrainXell has pioneered in producing highly enriched, functionally specialized neural cells from human stem cells, including cortical glutamate neurons, cortical GABA neurons, forebrain cholinergic neurons, striatal medium spinal GABA neurons, midbrain dopamine neurons, hindbrain serotonin neurons, spinal motor neurons, astrocytes, and oligodendrocytes. Importantly, these cells have been tested for their therapeutic potential in animal models of neurological diseases, including Huntington’s disease, Parkinson’s disease, epilepsy, spinal cord injury, and multiple sclerosis. We are currently examining the efficacy and safety of these cells in pre-clinical models of diseases. Meanwhile, we are building working cell banks in the GMP facility.


Utilizing proprietary technology developed by Professor Su-Chun Zhang at the University of Wisconsin-Madison, we direct human stem cells, including iPSCs (licensed from iPS Japan) to subtype-specific neuronal progenitors, which are expanded to large quantities, followed by rapid maturation. This unique combination of technology enables large-scale production of highly enriched, functionally specialized neural cells with consistent quality for drug discovery and cell therapy.